Hansa Biopharma AB (publ) announced that Ulf Wiinberg is not standing for re-election as director at its Annual General Meeting to be held on June 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.56 SEK | -4.51% |
|
-9.15% | +77.71% |
06-27 | Hansa Biopharma AB Announces Board Appointments | CI |
05-31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.71% | 311M | |
+21.89% | 47.96B | |
+0.90% | 42.45B | |
+43.96% | 41.47B | |
+26.43% | 31.6B | |
+21.01% | 28.63B | |
-4.47% | 28.03B | |
+52.17% | 14.56B | |
+45.20% | 14.14B | |
+2.87% | 12.58B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB Announces Ulf Wiinberg Not to Stand for Re-Election as Director